or Try an Advanced Search...

    Technical Analysis for GH - Guardant Health, Inc.

    Grade Last Price % Change Price Change
    C 27.10 -1.35% -0.37
    GH closed down 1.35 percent on Friday, May 31, 2024, on 1.51 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    7 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical GH trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Wide Bands Range Expansion -1.35%
    Overbought Stochastic Strength -1.35%
    Calm After Storm Range Contraction 3.87%
    Stochastic Reached Overbought Strength 3.87%
    Wide Bands Range Expansion 3.87%
    Overbought Stochastic Strength 3.87%
    Gapped Down Weakness 3.87%
    Older End-of-Day Signals for GH ...

       Recent Intraday Alerts

    Alert Time
    Down 1% 2 days ago
    Rose Above Previous Day's High 2 days ago
    Up 1% 2 days ago
    Up 5% 3 days ago
    Up 1 ATR 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    GH Chart by TradingView
    Basic chart:

    Profile

    Guardant Health, Inc. Description

    Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.

    Classification
    Sector: Healthcare
    Industry: Diagnostics & Research
    Keywords: Medicine Biopharmaceutical Cancer Disease Clinical Development Oncology Telehealth Telemedicine Lab Testing Precision Medicine Blood Test Biopsy Healthcare Costs

    Is GH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 31 Guardant Health Named to TIME100 Most Influential Companies
    May 30 Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
    May 30 Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares
    May 27 Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
    May 24 Evaluating Guardant Health: Insights From 5 Financial Analysts
    May 24 Guardant Health Jumps — As Exact Sciences Slumps — On A Key FDA Move For Blood Tests
    May 24 Guardant Health Stock Jumps. Blood Test for Cancer Moves Toward FDA Approval.
    May 24 Guardant Stock Climbs As Cancer Test Strides Towards FDA Ok
    May 24 Guardant jumps as trading resumes after FDA AdCom vote on cancer test
    May 24 FDA Advisory Panel Supports Approval Of Guardant Health's Blood Test For Colorectal Cancer Screening
    See more GH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 41.06
    52 Week Low 15.81
    Average Volume 2,396,579
    200-Day Moving Average 24.61
    50-Day Moving Average 20.21
    20-Day Moving Average 23.45
    10-Day Moving Average 25.11
    Average True Range 1.34
    RSI (14) 69.14
    ADX 37.37
    +DI 47.63
    -DI 14.86
    Chandelier Exit (Long, 3 ATRs) 23.86
    Chandelier Exit (Short, 3 ATRs) 21.88
    Upper Bollinger Bands 29.31
    Lower Bollinger Band 17.59
    Percent B (%b) 0.81
    BandWidth 50.00
    MACD Line 1.95
    MACD Signal Line 1.68
    MACD Histogram 0.2673
    Fundamentals Value
    Market Cap 3.29 Billion
    Num Shares 121 Million
    EPS -4.03
    Price-to-Earnings (P/E) Ratio -6.72
    Price-to-Sales 5.12
    Price-to-Book 12.02
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 28.51
    Resistance 3 (R3) 28.62 28.25 28.28
    Resistance 2 (R2) 28.25 27.89 28.20 28.20
    Resistance 1 (R1) 27.68 27.67 27.50 27.57 28.12
    Pivot Point 27.31 27.31 27.22 27.26 27.31
    Support 1 (S1) 26.74 26.95 26.56 26.63 26.08
    Support 2 (S2) 26.37 26.73 26.32 26.00
    Support 3 (S3) 25.80 26.37 25.93
    Support 4 (S4) 25.69